3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
13
Lymphoid
13
Other hematologic neoplasm
11
Myeloid
6
CNS
4
Dermatologic
3
Thoracic
2
Sarcoma
2
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
575
Carboplatin
521
Cisplatin
351
Bevacizumab
252
pembrolizumab
228
Gemcitabine
157
Topotecan
128
Cyclophosphamide
128
liposomal doxorubicin
127
olaparib
120
Taxes
113
Radiotherapy
110
Docetaxel
94
Brachytherapy
89
Doxorubicin
84
Drug Therapy
81
niraparib
75
Nivolumab
71
Magnetic Resonance Spectroscopy
71
Specimen Handling
65
fludarabine
57
Biopsy
55
Hyperthermic Intraperitoneal Chemotherapy
53
Filgrastim
52
Letrozole
50
Oxaliplatin
48
durvalumab
47
Immunoglobulin G
47
atezolizumab
46
Platinum
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Blood Component Removal
×
Gynecologic
×
Clear all
NCT05920798
2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2
Recruiting
40 enrolled